Phase 2/3 AD Study continues to make steady progress in patient recruitment Company to hold R&D webcast on Thursday, April 20th to review ongoing clinical programs in Alzheimer’s disease and Parkinson’s disease BERWYN, Pa., April 19, 2023 /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.